Unlocking Immunophenotyping and Disease Research: The Application Value of Mouse CD64 (FcγRI) Antibodies by ANT BIO PTE. LTD.

1. Concept

CD64, also known as high-affinity IgG Fc receptor type I (FcγRI), is a 71kD transmembrane glycoprotein encoded by a gene located on human chromosome 1 (with a homologous region in mice). Its extracellular domain contains three immunoglobulin-like domains. Under physiological conditions, CD64 exhibits high cell-specific expression—primarily on classical monocytes (CD14++ CD16- in humans; Ly-6Chi in mice) and tissue macrophages, serving as a definitive marker for these myeloid cells. Neutrophils express minimal CD64 at rest but undergo dynamic upregulation under pathological conditions. CD64 also emerges in myeloid-committed progenitor cells during hematopoiesis, making it a marker for granulocyte-monocyte progenitors. Mouse CD64 antibodies are essential tools for identifying, sorting, and analyzing monocytes, macrophages, and their precursor cells.

2. Research Frontiers

A key research frontier focuses on refining CD64 as a biomarker for bacterial infections and sepsis. Given its rapid upregulation on neutrophils during bacterial infections, researchers are exploring its utility for early diagnosis, severity assessment, and therapeutic monitoring—particularly in distinguishing bacterial from viral infections.

Another active area of investigation involves CD64’s role in hematologic malignancies. Studies are validating its value in subclassifying acute myeloid leukemia (AML) (e.g., AML-M4/M5) and exploring its prognostic significance, with evidence suggesting CD64 positivity correlates with favorable outcomes. Additionally, researchers are investigating abnormal CD64 expression in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) to develop it as a monitoring tool for clonal myeloid disorders.

Preclinical research frontiers also include using CD64 antibodies to study antibody-dependent cellular phagocytosis (ADCP) in anti-tumor and anti-infection immunity, as well as exploring CD64-targeted therapies for myeloid malignancies.

3. Research Significance

Investigating CD64 and leveraging mouse CD64 antibodies holds profound significance for both immunology research and clinical diagnostics. In basic research, these antibodies enable precise identification and functional analysis of myeloid cells, advancing our understanding of innate immune responses, infection, and inflammation. This knowledge forms the foundation for developing targeted immunotherapies.

Clinically, CD64 serves as a valuable biomarker for bacterial infections, sepsis, and hematologic malignancies, aiding in early diagnosis, subtype classification, and prognosis assessment. Mouse CD64 antibodies support preclinical development of diagnostic tools and therapies, accelerating the translation of experimental findings to clinical practice. Their use in disease models also facilitates the evaluation of novel treatments for infections and myeloid disorders.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

CD64’s core function lies in mediating high-affinity binding to IgG, triggering antibody-dependent cellular phagocytosis (ADCP) and immune activation. As illustrated in the flow cytometry plot, CD64 is specifically expressed on target myeloid cells, with minimal background staining. Its expression is dynamically regulated: IFN-γ strongly induces upregulation, while bacterial infections and sepsis rapidly increase CD64 levels on neutrophils. In hematologic malignancies, CD64 expression correlates with myeloid differentiation, particularly in monocytic AML subtypes.

Research Methods and Product Applications

Mouse CD64 antibodies are versatile tools supporting diverse research and preclinical applications. ANT BIO PTE. LTD.’s Mouse Anti-Human CD64 Antibody (Catalog No.: S0B0910) stands out for its high specificity, affinity, and stability, making it an essential reagent for immunophenotyping and disease research.

Key Applications of the Antibody:

• Myeloid Cell Identification and Sorting: The antibody enables specific isolation of monocytes, macrophages, or activated neutrophils from mouse peripheral blood, spleen, bone marrow, or inflammatory tissues via flow cytometry or immunomagnetic sorting, supporting downstream functional and transcriptional analyses.
• Infection and Sepsis Research: Dynamic monitoring of neutrophil CD64 expression using the antibody assesses infection severity, immune activation, and drug efficacy in mouse models of bacterial infection and sepsis.
• Hematologic Malignancy Studies: In mouse AML, MDS, or MPN models, the antibody aids in phenotypic identification, subtype classification, and tracking of leukemia stem/progenitor cells.
• ADCP and Functional Studies: Blocking CD64 with the antibody elucidates its role in ADCP during anti-tumor, anti-infection, or autoimmune responses, validating its function in immune regulation.
• Multicolor Flow Cytometry: The antibody integrates with other markers (e.g., CD14, CD16, HLA-DR) to construct complex panels for in-depth analysis of myeloid cell heterogeneity.

Core Advantages of the Antibody:

• Exceptional Specificity: The antibody specifically recognizes CD64, with minimal cross-reactivity to other Fcγ receptors (e.g., CD32, CD16). It accurately labels classical monocytes, macrophages, and activated neutrophils, ensuring reliable immunophenotyping.
• Superior Affinity and Signal-to-Noise Ratio: High affinity delivers bright, stable fluorescent signals in flow cytometry, enabling clear detection even in low-expression samples and precise gating.
• Rigorous Quality Control and Batch Consistency: Strict production standards ensure consistent concentration, potency, and specificity across batches, guaranteeing reproducible results for long-term studies and multicenter collaborations.

CD64 Expression in Hematologic Malignancies:

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to advancing life science research and clinical diagnostics by providing high-performance, high-value core reagents and comprehensive solutions. Leveraging advanced development platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development platforms (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—the company adheres to stringent quality standards and has successfully obtained EU 98/79/EC certification, ISO9001 certification, and ISO13485 certification. ANT BIO PTE. LTD. strives to support researchers and clinicians worldwide in their pursuit of scientific breakthroughs, improved patient care, and the development of innovative diagnostics and therapies for infections and hematologic malignancies.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.